Contravisory Investment Management Inc. purchased a new position in Insulet Co. (NASDAQ:PODD - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,113 shares of the medical instruments supplier's stock, valued at approximately $552,000.
Other hedge funds also recently made changes to their positions in the company. Blue Trust Inc. boosted its holdings in Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 58 shares during the period. Venturi Wealth Management LLC raised its position in shares of Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock worth $36,000 after buying an additional 133 shares in the last quarter. TD Private Client Wealth LLC raised its position in shares of Insulet by 32.6% in the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after buying an additional 56 shares in the last quarter. Friedenthal Financial bought a new position in Insulet in the 4th quarter worth about $57,000. Finally, Versant Capital Management Inc increased its stake in Insulet by 106.1% in the 4th quarter. Versant Capital Management Inc now owns 305 shares of the medical instruments supplier's stock worth $80,000 after acquiring an additional 157 shares during the last quarter.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on the company. Wells Fargo & Company boosted their price objective on Insulet from $290.00 to $305.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. TD Cowen increased their price target on shares of Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a report on Friday, January 3rd. Citigroup lifted their price objective on shares of Insulet from $283.00 to $310.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. JPMorgan Chase & Co. upped their target price on shares of Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a research report on Thursday, December 12th. Finally, Raymond James raised their price target on Insulet from $213.00 to $260.00 and gave the company an "outperform" rating in a research report on Monday, October 14th. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $272.81.
View Our Latest Research Report on Insulet
Insulet Trading Up 3.2 %
NASDAQ:PODD traded up $8.48 during midday trading on Thursday, reaching $272.86. 676,889 shares of the stock traded hands, compared to its average volume of 504,999. The stock has a market capitalization of $19.14 billion, a P/E ratio of 46.72, a PEG ratio of 3.41 and a beta of 1.22. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.77. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company has a fifty day moving average of $265.59 and a 200 day moving average of $231.62.
Insider Activity
In other news, CAO Lauren Budden sold 915 shares of the business's stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now directly owns 5,733 shares of the company's stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.47% of the company's stock.
Insulet Profile
(
Free Report)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
Further Reading
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
